. >> i thought it was wilt chamberlain, leading scorer. oh, oh, oh, points. ed more. the american society of clinical oncology kicking off its annual meeting. addressing this year's theme, building bridges to conquer cancer. joining us from now is chief medical officer at roche. i go back to the crazy biotech company working on antramed. it looked like it didn't work. evastin came along. >> it's been 10 years since the pivotal data that showed works in colon cancer. since then the data has shown that it works now in the united states, approved in four different types of cancer. we have had 26 late stage trials. in conjunction with chemotherapy. your trial showed it was positive at least in preventing the tumor for growing for a longer time, right? >> yeah. it was two very exciting programs. one in cervical cancer, the second most common cause of cancer-related deaths in women between ages of 15 and 45. it is sponsored by nci. women who received evastin had four-month improvement in living with their cancer. that's very impressive. and two studies in brain canc